Gozzi-Silva Sarah Cristina, Benard Gil, Alberca Ricardo Wesley, Yendo Tatiana Mina, Teixeira Franciane Mouradian Emidio, Oliveira Luana de Mendonça, Beserra Danielle Rosa, Pietrobon Anna Julia, Oliveira Emily Araujo de, Branco Anna Cláudia Calvielli Castelo, Andrade Milena Mary de Souza, Fernandes Iara Grigoletto, Pereira Nátalli Zanete, Ramos Yasmim Álefe Leuzzi, Lima Julia Cataldo, Provenci Bruna, Mangini Sandrigo, Duarte Alberto José da Silva, Sato Maria Notomi
Laboratory of Dermatology and Immunodeficiencies (LIM-56), Institute of Tropical Medicine of School of Medicine of São Paulo (FMUSP), 05403-000 São Paulo, Brazil.
Institute of Biomedical Sciences, University of São Paulo, 05508-000 São Paulo, Brazil.
Trop Med Infect Dis. 2021 Feb 10;6(1):22. doi: 10.3390/tropicalmed6010022.
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 has infected over 90 million people worldwide, therefore it is considered a pandemic. SARS-CoV-2 infection can lead to severe pneumonia, acute respiratory distress syndrome (ARDS), septic shock, and/or organ failure. Individuals receiving a heart transplantation (HT) may be at higher risk of adverse outcomes attributable to COVID-19 due to immunosuppressives, as well as concomitant infections that may also influence the prognoses. Herein, we describe the first report of two cases of HT recipients with concomitant infections by SARS-CoV-2, and cytomegalovirus (CMV) dissemination, from the first day of hospitalization due to COVID-19 in the intensive care unit (ICU) until the death of the patients.
2019冠状病毒病(COVID-19)由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起。COVID-19已在全球感染了超过9000万人,因此被视为大流行病。SARS-CoV-2感染可导致严重肺炎、急性呼吸窘迫综合征(ARDS)、感染性休克和/或器官衰竭。接受心脏移植(HT)的个体由于使用免疫抑制剂以及可能影响预后的合并感染,可能因COVID-19而面临更高的不良结局风险。在此,我们描述了两例HT受者的首例报告,他们在重症监护病房(ICU)因COVID-19住院的第一天就同时感染了SARS-CoV-2和巨细胞病毒(CMV)传播,直至患者死亡。